HST Global, Inc. Begins Selection of FDA Legal Team

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC), a development stage biotechnology company, today announced that it has asked EBITDA Capital to assist in the selection of its FDA legal team and EBITDA Capital has assigned the process to Roman Buhler.

Mr. Buhler served for 14 years as Counsel to the US House of Representatives Committee on House Administration, and currently runs his own lobbying and consulting practice in Washington D.C. He graduated from Stanford University and the University of Southern California Law School. Mr. Buhler is a member of the California Bar.

Mr. Buhler stated, “I am committed to the success of HST Global and to the goal of expediting FDA approval for the treatment it can offer for stage four cancer patients. I am enthusiastic about this mission to help expand opportunities for those who want to obtain treatment with the HST Global solution.”

Mr. Chet Noblett, Managing Partner, at EBITDA Capital stated, “I have been closely associated with Roman for many years and he is one of the most thorough individuals that I know. He not only understands the process of government but with his solid judgment and intellect he makes accurate and impactful decisions and recommendations. I am excited that he has accepted the assignment.”

About HST Global, Inc.

HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.